A detailed history of Jane Street Group, LLC transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Jane Street Group, LLC holds 369,671 shares of DNLI stock, worth $9.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
369,671
Previous 231,364 59.78%
Holding current value
$9.3 Million
Previous $5.37 Million 100.45%
% of portfolio
0.0%
Previous 0.01%

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$20.96 - $31.05 $2.9 Million - $4.29 Million
138,307 Added 59.78%
369,671 $10.8 Million
Q2 2024

Aug 14, 2024

BUY
$14.96 - $23.22 $2.73 Million - $4.24 Million
182,648 Added 374.92%
231,364 $5.37 Million
Q1 2024

May 15, 2024

SELL
$15.83 - $23.35 $1.59 Million - $2.34 Million
-100,249 Reduced 67.3%
48,716 $999,000
Q4 2023

Feb 14, 2024

BUY
$16.2 - $23.18 $1.79 Million - $2.56 Million
110,226 Added 284.53%
148,965 $3.2 Million
Q3 2023

Nov 14, 2023

SELL
$20.63 - $30.17 $702,678 - $1.03 Million
-34,061 Reduced 46.79%
38,739 $799,000
Q2 2023

Aug 14, 2023

SELL
$23.37 - $32.96 $1.01 Million - $1.42 Million
-43,005 Reduced 37.14%
72,800 $2.15 Million
Q1 2023

May 15, 2023

BUY
$21.91 - $32.67 $2.21 Million - $3.29 Million
100,836 Added 673.63%
115,805 $2.67 Million
Q4 2022

Feb 14, 2023

BUY
$26.28 - $33.92 $393,385 - $507,748
14,969 New
14,969 $416,000
Q2 2022

Aug 16, 2022

BUY
$20.88 - $35.19 $290,712 - $489,950
13,923 New
13,923 $410,000
Q1 2022

May 17, 2022

SELL
$29.0 - $47.27 $709,224 - $1.16 Million
-24,456 Closed
0 $0
Q4 2021

Feb 15, 2022

BUY
$42.59 - $55.02 $245,275 - $316,860
5,759 Added 30.8%
24,456 $1.09 Million
Q3 2021

Nov 16, 2021

BUY
$48.48 - $78.23 $697,336 - $1.13 Million
14,384 Added 333.5%
18,697 $943,000
Q2 2021

Aug 16, 2021

SELL
$50.3 - $78.44 $436,000 - $679,917
-8,668 Reduced 66.77%
4,313 $338,000
Q1 2021

May 18, 2021

SELL
$53.8 - $81.53 $1.06 Million - $1.6 Million
-19,613 Reduced 60.17%
12,981 $741,000
Q4 2020

Feb 17, 2021

BUY
$36.89 - $93.56 $101,373 - $257,102
2,748 Added 9.21%
32,594 $2.73 Million
Q3 2020

Nov 17, 2020

BUY
$23.13 - $38.84 $160,036 - $268,733
6,919 Added 30.18%
29,846 $1.07 Million
Q2 2020

Aug 17, 2020

SELL
$16.01 - $28.82 $256,784 - $462,243
-16,039 Reduced 41.16%
22,927 $554,000
Q1 2020

May 15, 2020

BUY
$14.2 - $27.98 $553,317 - $1.09 Million
38,966 New
38,966 $683,000
Q4 2019

Feb 14, 2020

SELL
$14.4 - $19.99 $186,854 - $259,390
-12,976 Closed
0 $0
Q3 2019

Nov 14, 2019

BUY
$15.32 - $21.92 $198,792 - $284,433
12,976 New
12,976 $199,000
Q4 2018

Feb 15, 2019

SELL
$13.88 - $21.75 $139,077 - $217,935
-10,020 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$12.46 - $21.74 $124,849 - $217,834
10,020 New
10,020 $218,000

Others Institutions Holding DNLI

About Denali Therapeutics Inc.


  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $3.38B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.